Tech Company Financing Transactions
Pathios Therapeutics Funding Round
Brandon Capital Partners, Bristol Myers Squibb and Canaan Partners participated in a $25 million Series B capital raise for Pathios Therapeutics. The round was announced on 4/18/2024.
Transaction Overview
Company Name
Announced On
4/18/2024
Transaction Type
Venture Equity
Amount
$25,000,000
Round
Series B
Proceeds Purpose
Proceeds from the raise will be used to support the continued development of Pathios' unique approach to cancer immunotherapy focused on the inhibition of GPR65, a novel target that has been genetically associated with a range of immunologically-mediated diseases.
Company Information
Company Status
Private & Independent
Industry
Healthcare Services
Mailing Address
99 Park Drive
Milton, Abingdon, OX14 4RY
UK
Milton, Abingdon, OX14 4RY
UK
Phone
Website
Email Address
Overview
Pathios Therapeutics is a drug discovery and development company that was established in 2017 by a team of experienced pharmaceutical industry professionals and biotech entrepreneurs. Based in Oxford, UK, the company is founded upon a deep understanding of the biology of the acidic TME and the immune cell receptor GPR65.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Tom McCarthy
Chief Executive Officer
Stuart Hughes
Chief Operating Officer
Shelley Cook
Vice President
David Miller
Browse more venture capital transactions:
Prev: 4/18/2024: dataPlor venture capital transaction
Next: 4/18/2024: Outrun Therapeutics venture capital transaction
Share this article
About Database of VC Transactions
We report on all VC transactions involving tech companies. VC investment data records reported here are sourced from publicly available VC deal announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs